ALKS 2680 Dose 2

DRUG3 trials

Sponsors

Alkermes, Inc.

Conditions

Narcolepsy Type 1Narcolepsy Type 2

Phase 3

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

RecruitingNCT07455383

Alkermes, Inc.Narcolepsy Type 1

Start: 2026-04-06End: 2027-06-01Target: 150Updated: 2026-09-03

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

RecruitingNCT07502443

Alkermes, Inc.Narcolepsy Type 2

Start: 2026-04-22End: 2027-06-01Target: 176Updated: 2026-09-03

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

RecruitingNCT07540897

Alkermes, Inc.Narcolepsy Type 1

Start: 2026-08-13End: 2027-07-01Target: 150Updated: 2026-09-03